Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price increased by B. Riley from $19.00 to $26.00 in a research report released on Monday morning, The Fly reports. The brokerage currently has a buy rating on the biotechnology company’s stock. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ Q4 2019 earnings at $0.04 EPS, FY2019 earnings at $0.57 EPS, FY2020 earnings at ($0.47) EPS and FY2021 earnings at ($1.15) EPS.

Several other equities analysts also recently commented on ARWR. Chardan Capital reaffirmed a buy rating and set a $24.50 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, February 11th. BidaskClub raised shares of Arrowhead Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, February 14th. Cantor Fitzgerald set a $24.00 price objective on shares of Arrowhead Pharmaceuticals and gave the company a buy rating in a research note on Friday, April 12th. Finally, Piper Jaffray Companies upped their price objective on shares of Arrowhead Pharmaceuticals from $25.00 to $33.00 and gave the company an overweight rating in a research note on Tuesday, April 16th. Seven investment analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and an average price target of $23.86.

Shares of NASDAQ:ARWR opened at $19.17 on Monday. The stock has a market cap of $1.71 billion, a PE ratio of -29.43 and a beta of 2.15. Arrowhead Pharmaceuticals has a 12 month low of $9.35 and a 12 month high of $22.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.22 by $0.02. The firm had revenue of $48.15 million during the quarter, compared to the consensus estimate of $45.78 million. Arrowhead Pharmaceuticals had a net margin of 10.09% and a return on equity of 6.72%. On average, sell-side analysts predict that Arrowhead Pharmaceuticals will post 1.06 EPS for the current year.

In related news, CEO Christopher Richard Anzalone sold 50,000 shares of the stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $19.30, for a total value of $965,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Bruce D. Given sold 42,500 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $19.99, for a total transaction of $849,575.00. Following the completion of the transaction, the chief operating officer now directly owns 687,106 shares of the company’s stock, valued at $13,735,248.94. The disclosure for this sale can be found here. Over the last three months, insiders sold 306,000 shares of company stock valued at $5,762,338. 4.80% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC bought a new position in Arrowhead Pharmaceuticals in the fourth quarter worth about $52,000. First Quadrant L P CA grew its holdings in Arrowhead Pharmaceuticals by 831.4% in the first quarter. First Quadrant L P CA now owns 3,353 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 2,993 shares during the period. Advisor Group Inc. grew its holdings in Arrowhead Pharmaceuticals by 73.4% in the fourth quarter. Advisor Group Inc. now owns 8,670 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 3,670 shares during the period. Wealth Architects LLC purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $124,000. Finally, Beaumont Financial Partners LLC purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $124,000. 62.38% of the stock is owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Recommended Story: How to Invest in a Bull Market

The Fly

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.